BRIACELL THERAPEUTICS CORP. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
BRIACELL THERAPEUTICS CORP. (BCTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 100.00% for the 12-month period ending 2023-07-31, per its 10-K filed 2024-10-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2025-10-16
- BRIACELL THERAPEUTICS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-10-31 was 100.00%.
- BRIACELL THERAPEUTICS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 100.00%, a 0.00% change from fiscal 2022.
- BRIACELL THERAPEUTICS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 100.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|
| 2023-07-31 | 100.00% 10-K · filed 2024-10-29 | ||||
| 2023-04-30 | 100.00% 10-Q · filed 2023-06-14 | ||||
| 2023-01-31 | 100.00% 10-Q · filed 2023-03-16 | ||||
| 2022-10-31 | 100.00% 10-Q · filed 2022-12-14 | ||||
| 2022-07-31 | 100.00% 10-K · filed 2023-10-25 | ||||
| 2021-06-03 | 100.00% 10-K · filed 2022-10-28 | ||||
| 2021-04-12 | 100.00% 10-K · filed 2025-10-16 | ||||
| 2021-02-26 | 100.00% 10-K · filed 2025-10-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |